Analyst Price Targets — SRPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 27, 2026 2:45 pm | — | Morgan Stanley | $25.00 | $16.28 | TheFly | Morgan Stanley says Sarepta's CEO transition brings clarity ahead of catalysts |
| July 9, 2026 11:14 am | — | Piper Sandler | $20.00 | $20.21 | TheFly | Sarepta price target lowered to $20 from $23 at Piper Sandler |
| July 8, 2026 9:07 pm | — | Wolfe Research | $27.00 | $20.21 | TheFly | Sarepta upgraded to Outperform from Peer Perform at Wolfe Research |
| May 15, 2026 12:25 pm | — | Evercore ISI | $19.00 | $18.20 | TheFly | Sarepta price target lowered to $19 from $20 at Evercore ISI |
| March 26, 2026 12:39 pm | — | Deutsche Bank | $14.00 | $21.68 | TheFly | Deutsche ups Sarepta target, says 35% stock rally overdone |
| March 26, 2026 12:30 pm | — | Wedbush | $35.00 | $21.68 | TheFly | Sarepta price target raised to $35 from $29 at Wedbush |
| March 12, 2026 9:06 pm | Uy Ear | Mizuho Securities | $31.00 | $17.04 | StreetInsider | Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho |
| March 3, 2026 8:44 pm | Ilya Zubkov | Loop Capital Markets | $25.00 | $15.87 | StreetInsider | Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets |
| March 3, 2026 5:00 pm | Andrew Tsai | Jefferies | $30.00 | $15.98 | StreetInsider | Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story" |
| January 27, 2026 12:18 pm | — | Robert W. Baird | $22.00 | $22.80 | TheFly | Sarepta price target raised to $22 from $15 at Baird |
Latest News for SRPT
Canada Pension Plan Investment Board purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 70,800 shares of the biotechnology company's stock, valued at approximately $1,272,000. Canada Pension Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live under the investor relations section of Sarepta's website at…
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”).Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important…
Bank of America Corp DE increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 26.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,145,926 shares of the biotechnology company's stock after buying an additional 450,336 shares during the
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRPT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.